Monday, May 12


Data at The ECTRIMS Meetings will be presented from across Biogen Idec’s portfolio, including:

Investigational medicines:

PLEGRIDY(pegylated interferon beta-1a): a potential new molecular entity for relapsing forms of MS in which interferon beta-1a is pegylated to extend its half-life and prolong its exposure in the body. Pegylation offers a less-frequent dosing schedule.

DACLIZUMAB HIGH-YIELD PROCESS (DAC HYP): is being developed as a once-monthly subcutaneous injection. DAC HYP is believed to target the activated immune cells that can play a key role in MS without causing general immune cell depletion. DAC HYP is being developed under a collaboration agreement with AbbVie, Inc.

Anti-LINGO-1 (BIIB033): is the first candidate being investigated for its potential to repair neurons damaged by MS.

Approved medicines:

TYSABRI® (natalizumab): offers established efficacy that has been proven to reduce relapses and slow disability progression.

TECFIDERA® (dimethyl fumarate): an oral treatment for relapsing forms of MS, including relapsing-remitting MS (RRMS), which has been clinically proven to significantly reduce important measures of disease activity with a favorable safety/tolerability profile. TECFIDERA is currently approved in the United States, Canada and Australia.

FAMPYRA® (prolonged-release fampridine tablets): the first approved treatment to address the unmet medical need of walking improvement in MS patients, demonstrating efficacy in patients with all MS types. Approved in the European Union.

The titles of key Biogen Idec abstracts are as follows:


October 3

Poster #519: Effects of natalizumab treatment on freedom from disease activity by baseline characteristics in AFFIRM
Poster #524: Natalizumab reduces the disabling amplitude of multiple sclerosis relapses and improves post-relapse residual disability
October 4

Poster #1050: Disease activity and disability progression decrease beyond two years on natalizumab in relapsing multiple sclerosis patients in the TYSABRI® (natalizumab) Observational Programme

October 3

Poster #538: 4-year follow-up of oral BG-12 (dimethyl fumarate) treatment in relapsing remitting multiple sclerosis (RRMS): integrated clinical efficacy data from the DEFINE, CONFIRM, and ENDORSE studies
October 4

Poster #1004: 4-year follow-up of oral BG-12 (dimethyl fumarate) treatment in relapsing remitting multiple sclerosis (RRMS): integrated magnetic resonance imaging (MRI) outcomes from DEFINE, CONFIRM, and ENDORSE
Poster #1127: Interim analysis of quality of life in patients with relapsing remitting multiple sclerosis treated with BG-12 (dimethyl fumarate) in the ENDORSE study
Poster #996: Safety profile of BG-12 (dimethyl fumarate) in relapsing remitting multiple sclerosis: long-term interim results from the ENDORSE extension study
Poster #990: Effect of BG-12 (dimethyl fumarate) in newly diagnosed relapsing remitting multiple sclerosis (RRMS) patients from the DEFINE and CONFIRM studies
Poster #1100: Dimethyl fumarate and monomethyl fumarate are distinguished by non-overlapping pharmacodynamic effects in vivo

October 3

Poster #665: Long-term prolonged-release fampridine treatment and health-related quality of life outcomes: nine-month interim analysis of the ENABLE study
Poster #658: Health-related quality of life outcomes following long-term treatment with prolonged-release fampridine: impact on psychological outcomes in the ENABLE study
October 4

Poster #1128: Changes in physical functioning and activity following long-term treatment with prolonged-release fampridine in the ENABLE study

October 3

Poster #514: Peginterferon beta-1a provides improvements in clinical and radiological disease activity in relapsing-remitting multiple sclerosis: year 1 findings from the phase 3 ADVANCE study
October 4

Poster #989: Magnetic resonance imaging results from the first year of the ADVANCE study, a pivotal phase 3 trial of peginterferon beta-1a in patients with relapsing-remitting multiple sclerosis

October 3

Poster #545: The use of magnetic resonance imaging to monitor the safety of anti-LINGO-1: findings from phase I studies in healthy volunteers and subjects with multiple sclerosis
Poster #378: Blocking LINGO1 promotes axonal regeneration in the rat optic nerve crush model

October 4

Poster #977: Reduction in brain atrophy with extended daclizumab HYP treatment: results of SELECT and the SELECT extension study
Poster #864: Evaluation of immunogenicity in multiple sclerosis patients continuously treated with daclizumab-HYP during the SELECT and SELECTION clinical trials.